Skip to main content
Premium Trial:

Request an Annual Quote

Stephen David, Sunny Tam, Douglas Hinerfeld, Will Brooke, Mark Grovic, Ofer Haviv, Martin Gerstel, Leon Recanati, and Ilan Chet

Premium

Stephen David has joined Nonlinear Dynamics' strategic marketing team, the Newcastle upon Tyne, UK-based company said this week. He comes to Nonlinear from GE Healthcare, formerly Amersham Biosciences, where he worked as DiGE global applications specialist.


Sunny Tam (see Proteomics Pioneer) has joined the University of Massachusetts Medical School as research associate professor, and Douglas Hinerfeld as research assistant professor, both of biochemistry and molecular pharmacology, UMMS said last week. The two researchers come to UMMS from Charles River Proteomic Services, which closed down last year. They will participate in running the new UMMS Proteomic Consortium (see UMMS story).


Will Brooke and Mark Grovic have joined the board of directors of pathogen detection firm Innovative Biosensors of College Park, Md., in conjunction with the company's recent Series A round, Innovative said last week. Brooke works for Harbert Venture Partners and Grovic for New Markets Growth Fund, both investors in the financing round.


Ofer Haviv has been promoted to president and chief executive officer of Evogene, the Rehovot, Israel-based company, a subsidiary of Compugen, said yesterday. He used to be the company's chief operating and financial officer. He replaces Hagai Karchi, who has switched to the position of chief scientific officer.

In addition, Martin Gerstel, chairman of Compugen, has been appointed chairman of Evogene's board of directors. Leon Recanati, chairman and CEO of GlenRock Israel, has been elected as director, and Ilan Chet, president of the Weizmann Institute, as a special advisor to the company's board.

 

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.